BACKGROUND/ OBJECTIVES: The histone deacetylases SIRT1 and SIRT2 have been shown to be involved in the differentiation of rodent adipocyte precursors. In light of the differences in gene expression and metabolic function of visceral (V) and subcutaneous (S) adipose tissue (AT) and their resident cells, the aim of this study was to investigate the role of SIRT1 and SIRT2 in the differentiation of adipose stem cells (ASCs) isolated from SAT and VAT biopsies of nondiabetic obese and nonobese individuals. METHODS: Human ASCs were isolated from paired SAT and VAT biopsies obtained from 83 nonobese and 92 obese subjects and were differentiated in vitro. Adipogenesis was evaluated by analyzing the lipid deposition using an image processing software, and gene expression by RT-qPCR. SIRT1 and SIRT2 protein expression was modified by using recombinant adenoviral vectors. RESULTS: Visceral but not subcutaneous ASCs from obese subjects showed an intrinsic increase in both adipogenesis and lipid accumulation when compared with ASCs from nonobese subjects, and this was associated with reduced SIRT1 and SIRT2 mRNA and protein levels. Moreover, adipose tissue mRNA levels of SIRT1 and SIRT2 showed an inverse correlation with BMI in the visceral but not subcutaneous depot. Overexpression of SIRT1 or SIRT2 in visceral ASCs from obese subjects resulted in inhibition of adipocyte differentiation, whereas knockdown of SIRT1 or SIRT2 in visceral ASCs from nonobese subjects enhanced this process. Changes in SIRT1 or SIRT2 expression and adipocyte differentiation were paralleled by corresponding changes in PPARG, CEBPA, and other genes marking terminal adipocyte differentiation. CONCLUSIONS: SIRT1 and SIRT2 modulate the differentiation of human ASC. Reduced expression of SIRT1 and SIRT2 may enhance the differentiation capacity of visceral ASC in human obesity, fostering visceral adipose tissue expansion.
BACKGROUND/ OBJECTIVES: The histone deacetylases SIRT1 and SIRT2 have been shown to be involved in the differentiation of rodent adipocyte precursors. In light of the differences in gene expression and metabolic function of visceral (V) and subcutaneous (S) adipose tissue (AT) and their resident cells, the aim of this study was to investigate the role of SIRT1 and SIRT2 in the differentiation of adipose stem cells (ASCs) isolated from SAT and VAT biopsies of nondiabetic obese and nonobese individuals. METHODS:Human ASCs were isolated from paired SAT and VAT biopsies obtained from 83 nonobese and 92 obese subjects and were differentiated in vitro. Adipogenesis was evaluated by analyzing the lipid deposition using an image processing software, and gene expression by RT-qPCR. SIRT1 and SIRT2 protein expression was modified by using recombinant adenoviral vectors. RESULTS: Visceral but not subcutaneous ASCs from obese subjects showed an intrinsic increase in both adipogenesis and lipid accumulation when compared with ASCs from nonobese subjects, and this was associated with reduced SIRT1 and SIRT2 mRNA and protein levels. Moreover, adipose tissue mRNA levels of SIRT1 and SIRT2 showed an inverse correlation with BMI in the visceral but not subcutaneous depot. Overexpression of SIRT1 or SIRT2 in visceral ASCs from obese subjects resulted in inhibition of adipocyte differentiation, whereas knockdown of SIRT1 or SIRT2 in visceral ASCs from nonobese subjects enhanced this process. Changes in SIRT1 or SIRT2 expression and adipocyte differentiation were paralleled by corresponding changes in PPARG, CEBPA, and other genes marking terminal adipocyte differentiation. CONCLUSIONS:SIRT1 and SIRT2 modulate the differentiation of humanASC. Reduced expression of SIRT1 and SIRT2 may enhance the differentiation capacity of visceral ASC in humanobesity, fostering visceral adipose tissue expansion.
Authors: Kirsty L Spalding; Erik Arner; Pål O Westermark; Samuel Bernard; Bruce A Buchholz; Olaf Bergmann; Lennart Blomqvist; Johan Hoffstedt; Erik Näslund; Tom Britton; Hernan Concha; Moustapha Hassan; Mikael Rydén; Jonas Frisén; Peter Arner Journal: Nature Date: 2008-05-04 Impact factor: 49.962
Authors: Tamara Tchkonia; Thomas Thomou; Yi Zhu; Iordanes Karagiannides; Charalabos Pothoulakis; Michael D Jensen; James L Kirkland Journal: Cell Metab Date: 2013-04-11 Impact factor: 27.287
Authors: S Perrini; L Laviola; A Cignarelli; M Melchiorre; F De Stefano; C Caccioppoli; A Natalicchio; M R Orlando; G Garruti; M De Fazio; G Catalano; V Memeo; R Giorgino; F Giorgino Journal: Diabetologia Date: 2007-10-25 Impact factor: 10.122
Authors: Josefine Lindroos; Julia Husa; Gerfried Mitterer; Arvand Haschemi; Sabine Rauscher; Robert Haas; Marion Gröger; Robert Loewe; Norbert Kohrgruber; Klaus F Schrögendorfer; Gerhard Prager; Harald Beck; J Andrew Pospisilik; Maximilian Zeyda; Thomas M Stulnig; Wolfgang Patsch; Oswald Wagner; Harald Esterbauer; Martin Bilban Journal: Cell Metab Date: 2013-07-02 Impact factor: 27.287
Authors: Erik Arner; Pål O Westermark; Kirsty L Spalding; Tom Britton; Mikael Rydén; Jonas Frisén; Samuel Bernard; Peter Arner Journal: Diabetes Date: 2009-10-21 Impact factor: 9.461
Authors: Tani Leigh; Tatsuo Kawai; Kyle Preston; Sheri Kelemen; Rachael Okune; Amanda St Paul; Cali Corbett; Amanda M Peluzzo; Jun Yu; Rosario G Scalia; Michael V Autieri Journal: Am J Pathol Date: 2022-04-20 Impact factor: 5.770
Authors: R Spinelli; L Parrillo; M Longo; P Florese; A Desiderio; F Zatterale; C Miele; G Alexander Raciti; F Beguinot Journal: J Endocrinol Invest Date: 2020-05-01 Impact factor: 4.256
Authors: Sara Cruciani; Giuseppe Garroni; Francesca Balzano; Renzo Pala; Emanuela Bellu; Maria Laura Cossu; Giorgio Carlo Ginesu; Carlo Ventura; Margherita Maioli Journal: Int J Mol Sci Date: 2020-08-27 Impact factor: 5.923